cln-081
Small moleculeexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
5
Phase 3
2
Phase 4
0
Earliest trial started Sep 15, 2019 (NCT04036682)
Timeline
Indications
Mechanism of action
Epidermal growth factor receptor erbB1 inhibitor
Increased activity against EGFR mutants vs. wild-type
Increased activity against EGFR mutants vs. wild-type
Chemistry & pharmacology
Loading structure…
SMILES
C=CC(=O)N[C@H]1C=C(C)c2c(-c3cnc4ccccc4c3)c3c(N)ncnc3n2C1- Mol. weight
- 396.45 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650281 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07229339 | Phase 2 | Dec 1, 2025 | Otsuka, University of California, Los Angeles |
| NCT07128199 | Phase 3 | Nov 30, 2025 | Otsuka |
| NCT05967689 | Phase 2 | Jul 27, 2023 | Otsuka |
| NCT05973773 | Phase 3 | Jun 30, 2023 | Otsuka |
| NCT04036682 | Phase 1/Phase 2 (Phase 2) | Sep 15, 2019 | Cullinan Oncology, LLC, Harvard University |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Otsuka | For profit | 4 | 3 | 2 | 2023 |
| Cullinan Oncology, LLC | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| University of California, Los Angeles | Academic/Hospital | 1 | 1 | 1 | 2025 |
4 organizations
Page 1 / 1